Strategies that enhance the efficacy of adoptive therapy involve intrinsic factors such as the selection of desired effector cells and extrinsic factors such as patient conditioning. Ex vivo expanded antigen-specific T cell clones allows us to evaluate these factors in clinical trials for the treatment of patients with metastatic melanoma. In one trial, adoptively transferred antigen-specific CD8+ T cell clones were examined in patients following Fludarabine lymphodepletion; in the second, CD4 T cell clones were administered in a dose escalation study. The safety, duration of in vivo persistence, and anti-tumor efficacy of these trials will be presented along with considerations for future studies.
This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.
- Copyright © 2007 by Cassian Yee